Loading…
Loading…
CDBT (China Dasheng Biotechnology Company) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CDBT does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CDBT and 80,000+ other tickers.
See exactly how CDBT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CDBT and 80,000+ other tickers.
China Dasheng Biotechnology Company, alongside its various divisions, is dedicated to the creation, promotion, and distribution of microbial products within the People's Republic of China. These specialized solutions primarily function as beneficial additives for both livestock feed and agricultural cultivation. The company's product line features proprietary blends of Artificial Microorganisms (AM) and High-efficiency Microorganisms (HM), in addition to biological preservatives. Its AM/HM bacteria-based additives for crops, including specific strains like Bulgaria lactobacillus, beer…
ARUNDEL, AUSTRALIA / ACCESSWIRE / December 16, 2023 / China Dasheng Biotechnology Co. (OTC Pink: CDBT) advises that it has been issued 2 Judgements, $17,129.13 and $17,066.59 in its favor against Kenneth Maciora and Empire Relations Group, Inc., and those Judgements have been registered with the Magistrates Court of Queensland on November 29, 2023. Background: As disclosed on October 9, 2023, CDBT formally terminated the China Dasheng Biotechnology Co. Consulting Agreement with Kenneth Maciora, Empire Relations Group Inc., and Empire Holdings LLC.
ARUNDEL, AUSTRALIA / ACCESSWIRE / October 9, 2023 / China Dasheng Biotechnology Co. (OTC PINK:CDBT) advisors that the company has terminated the China Dasheng Biotechnology Co. Consulting Agreement with Kenneth Maciora, Empire Relations Group, Inc. and Empire Relations Holdings LLC. On July 10, 2023, CDBT entered the China Dasheng Biotechnology Co. Consulting Agreement which had a 3-month period expiring on October 10, 2023, with an upfront fee and an extension of a further 3 months.
China Dasheng Biotechnology Co. OTC-CDBT (to be renamed Cycclone Magnetic Engines, Inc.) ARUNDEL, QUEENSLAND, AUSTRALIA / ACCESSWIRE / August 29, 2023 / China Dasheng Biotechnology Co. (OTC PINK:CDBT) announces founder, shareholder and stakeholder approval for all Cycclone Magnetic Engine related technology and intellectual property to become housed under China Dasheng Biotechnology, Co. (to be renamed Cycclone Magnetic Engines, Inc.) Through the month of August 2023, documents have been signed by founders, shareholders, and stakeholders to formalize the bringing together of the various subsidiaries and intellectual property associated with Cycclone Magnetic Engines being vested into CDBT. Added to this, 2 shareholder meetings were held, one at the Yatala transport facility and the other at the Bangalow small component facility with a "show of hands vote", which was unanimous at both meetings.